{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007839","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.672493+00:00","generated_at":"2026-05-15T13:31:42.859548+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pulse Biosciences enrolls first patients in thyroid cancer feasibility study of Vybrance nsPFA system","bullets":["First-in-human cases completed at Sarasota Memorial and MD Anderson for T1N0M0 papillary thyroid microcarcinoma.","Study is a multicenter, prospective feasibility trial; 30 patients planned across two sites.","System has FDA 510(k) clearance for soft tissue ablation; study runs under IDE for thyroid indications.","Primary endpoints: safety and effectiveness of nsPFA in treating tumors <1.5 cm."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007839","json":"https://secwatch.observer/filing/0001437749-26-007839.json","markdown":"https://secwatch.observer/filing/0001437749-26-007839.md","text":"https://secwatch.observer/filing/0001437749-26-007839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926007839/0001437749-26-007839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926007839/plse20260309_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:31:42.859548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}